High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography–tandem mass spectrometry
- 6 February 2002
- journal article
- Published by Elsevier in Journal of Chromatography B
- Vol. 768 (2) , 325-340
- https://doi.org/10.1016/s1570-0232(01)00611-0
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorNew England Journal of Medicine, 2001
- Chronic myeloid leukaemiaEuropean Journal Of Cancer, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitorsDrug Discovery Today, 2000
- Protein Tyrosine Kinase Structure and FunctionAnnual Review of Biochemistry, 2000
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJournal of Clinical Investigation, 2000
- Atmospheric Pressure Ionization LC/MS/MS Techniques for Drug Disposition StudiesJournal of Pharmaceutical Sciences, 1998
- Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivativesBioorganic & Medicinal Chemistry Letters, 1997